Related Experiment Video
Updated: Jun 24, 2026
Murine Model of Allergen Induced Asthma
Published on: May 14, 2012
Therapeutic target validation of protein kinase C(PKC)-zeta for asthma using a mouse model
Jeong-Su Do1, Kang-Seo Park, Hyo-Jung Seo
1Department of Biological Science, School of Science and Technology, Jeonju University, Jeonju 560-759, Korea.
Abstract:
Protein kinase C (PKC) is a complex family consisting of many types of isoenzymes, of which PKC-zeta, an atypical isoform, has been reportedly implicated in the regulation of apoptosis and NF-kappaB, as well as control of T-dependent responses. Based on the recent report that PKC-zeta controls TH2 response, the current study was aimed to evaluate PKC-zeta as a potential therapeutic target for asthma using a mouse model. Mouse allergic asthma was induced by repeated sensitization followed by intranasal challenge with OVA and PKC-zeta pseudosubstrate inhibitor (PPI) was intratracheally instilled before each OVA challenge. Airway hyperreactivity (AHR) was measured by beta-methacoline-induced airflow obstruction. Cellular and cytokine profile in bronchoalveolar lavage fluid (BALF) and level of serum IgE as well as cytokine production by draining lymph node cells were compared. AHR and numbers of eosinophils in BALF were significantly lowered by PPI, indicating that blocking of PKC-zeta activation alleviates asthmatic manifestations. Additionally, PPI instillation decreased IL-5 and IL-13 levels in BALF to approximately 20% of controls, but not IFN-gamma level. Instillation of PPI also caused a marked fall in the level of TNF-alpha, another NF-kappaB-dependent, proinflammatory cytokine. Serum OVA-specific IgE level and ex vivo IL-4, IL-5 and IL-13, but not IFN-gamma, production by peribronchial lymph node cells was also considerably lower in PPI-treated mice. In conclusion, blockade of PKC-zeta signals by intratracheal instillation of PPI alleviates allergen-specific TH2 response as well as asthmatic manifestations and hence PKC-zeta is a promising target for treatment of asthma.
Insights
This study shows that blocking Protein Kinase C-zeta (PKC-zeta) with an inhibitor reduces allergic asthma symptoms in mice. Targeting PKC-zeta effectively alleviates airway hyperreactivity and TH2 responses, suggesting its potential as an asthma therapy.
Area of Science:
- Immunology
- Pharmacology
- Molecular Biology
Background:
- Protein Kinase C (PKC) is a family of enzymes with various isoforms.
- PKC-zeta, an atypical isoform, is involved in apoptosis, NF-kappaB regulation, and T-cell responses.
- Recent findings suggest PKC-zeta plays a role in controlling T-helper 2 (TH2) immune responses.
Purpose of the Study:
- To investigate the potential of targeting PKC-zeta as a therapeutic strategy for allergic asthma.
- To evaluate the efficacy of a PKC-zeta pseudosubstrate inhibitor (PPI) in a mouse model of asthma.
Main Methods:
- Allergic asthma was induced in mice via ovalbumin (OVA) sensitization and challenge.
- PKC-zeta pseudosubstrate inhibitor (PPI) was administered intratracheally.
- Airway hyperreactivity (AHR) was assessed using methacholine challenges.
- Analysis of bronchoalveolar lavage fluid (BALF) for cellular and cytokine profiles, serum IgE levels, and cytokine production from lymph node cells.
Main Results:
- PPI treatment significantly reduced airway hyperreactivity and eosinophil counts in BALF.
- Instillation of PPI markedly decreased levels of IL-5, IL-13, and TNF-alpha in BALF.
- Serum OVA-specific IgE and ex vivo production of IL-4, IL-5, and IL-13 by lymph node cells were significantly lower in PPI-treated mice.
- IFN-gamma levels were not significantly affected by PPI treatment.
Conclusions:
- Blockade of PKC-zeta signaling through intratracheal PPI administration effectively alleviates asthmatic manifestations.
- Targeting PKC-zeta dampens allergen-specific TH2 responses, indicating its promise as a therapeutic target for asthma treatment.
